In resource limited settings, induction chemotherapy with @entity136 and @entity900 and concurrent hypofractionated chemoradiation for locally advanced @entity189 (BMSCC) are a cost effective option but remain under reported. The objective of this study was to report long term survival outcome after concurrent hypofractionated radiotherapy in locally advanced BMSCC. Between February 2005 and 2009, 63 @entity1 received treatment. Induction chemotherapy (IC) regimen consisted of two drugs: @entity136 and @entity900 . All @entity1 received 55   Gy of radiation in 20 fractions with concurrent single agent @entity900 (75   mg/m(2)). Five-year overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) were determined. Based on AJCC staging, 7 (11%) @entity1 were stage III, 31 (49%) stage IV a, and 25 (40%) stage IVb at presentation. After IC, 8 (18%) @entity1 had complete radiological response, 33 (73%) had partial response, and 4 (9%) had stable disease. After concurrent hypofractionated chemoradiation, thirty-nine (62%) @entity1 were complete responders and 24 (38%) had stable disease. With a minimum follow-up of 60 months, 5-year OS, DFS, and PFS were 30%, 49%, and 30%, respectively. In locally advanced @entity957 , concurrent hypofractionated chemoradiation results in acceptable survival and regimen related @entity137 .

Five-Year Follow-Up of Concomitant Accelerated Hypofractionated Radiation in Advanced Squamous Cell XXXX : A Retrospective Cohort Study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity957 :: ('MESH:D002294', 'Disease') :: ['buccal mucosa squamous cell carcinoma'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['Cisplatin', 'Cisplatinum'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma of buccal mucosa'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine']
@entity189 :: (MESH:D002277,Disease) :: ['Carcinoma of the Buccal Mucosa']
